According to incomplete statistics from Chuangjian Hui,Last week (November 3 to November 9), a total of 31 transaction events were disclosed in the global biopharmaceutical field, with a potential total transaction value exceeding $8.8 billion.。

For many years, designing molecules that can safely cross the blood-brain barrier has been a challenge in neuro-drug development. As an explorer who has been deeply engaged in this field for fifteen years,Last week, Roche announced a collaboration with Manifold Bio worth over $2 billion. The partnership will leverage Manifold Bio's proprietary AI-driven in vivo drug discovery system, mDesign, and its portfolio of tissue-targeting delivery vehicles to develop blood-brain barrier (BBB) delivery vehicles for neurological diseases.These carriers are designed to safely and efficiently deliver therapeutic payloads (such as antibodies, oligonucleotides, etc.) to the brain. Manifold's unique platform enables the direct in vivo testing of thousands to millions of biological variants, providing a wealth of physiologically relevant data that could accelerate the development of neurotherapeutic drugs.

In the field of metabolic diseases,SANEGENEBIO Partners with Eli Lilly on $1.2 Billion R&D Collaboration and Licensing Agreement to Develop RNAi Drugs for Metabolic Diseases Using Proprietary LEAD (Ligand-Enhanced And Delivery) Platform. This platform technology is expected to produce breakthrough therapies: with subcutaneous injection, patients only need to be dosed twice a year to maintain efficacy. SANEGENEBIO will be responsible for the discovery and optimization of early candidate drugs, while Eli Lilly will handle subsequent IND application studies, clinical development, and commercialization.

In addition,Last week, Eli Lilly also signed a cooperation agreement with Ailux Biologics, a subsidiary of XtalPi, totaling $345 million.Lilly will leverage Ailux's AI bispecific antibody engineering platform to accelerate the development of bispecific antibodies for various diseases. Lilly has the option to nominate multiple sets of targets and may gain access to Ailux’s platform.

TransThera and Neurocrine Biosciences Reach Collaboration Agreement Potentially Worth Over $880 Million to Develop NLRP3 Inhibitor for Treatment of Multiple DiseasesNeurocrine obtains exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors outside of Greater China.

In the field of anti-tumor,Incyte Reaches Exclusive Option Agreement with Prelude Therapeutics Worth Up to $910 MillionIncyte Obtains Exclusive Option to Acquire Prelude’s Mutant-Selective JAK2V617F JH2 Inhibitor Program Targeting Myeloproliferative Neoplasms (MPNs)Key Driver Mutation JAK2V617F`, is expected to achieve mutation-specific inhibition.`

For other transactions, see the table below.

Readers, please star ⭐ Chuangjianhui to receive updates第一时间收到推送.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Individuals are welcome to share this to their Moments. Unauthorized media or institutions are prohibited from reprinting or duplicating it in any form to other platforms. For reprint authorization, please contact:"Chuangjian Hui"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommendations

Click "InSee", Share Chuangjian Hui Health New Dynamics